据《华尔街日报》报道，由OpenAI支持的生物安全初创公司Red Queen Bio已筹集总计3600万美元，用于设计针对病毒的抗体药物，包括AI系统未来可能帮助制造的病毒。
Red Queen Bio, a biosecurity startup backed by OpenAI, has raised $36 million in total to design antibody drugs against viruses, including ones that AI systems could one day help create, The Wall Street Journal reported.
据该报称，该公司首先从针对禽流感和其他流感病毒的抗体入手，并计划于2027年进行首次临床试验。之后，它希望针对冠状病毒、类埃博拉病毒和天花近亲病毒。
The company is starting with antibodies against bird flu and other influenza viruses and plans its first clinical trials in 2027, according to the Journal. It later wants to target coronaviruses, Ebola-like viruses and relatives of smallpox.
设计、测试、重复 Red Queen利用AI设计能与病毒靶点紧密结合的抗体。它在实验室中培养细胞以生产和测试候选抗体，然后将结果反馈到其模型中，以设计更好的版本。
Design, test, repeat Red Queen uses AI to design antibodies that bind tightly to viral targets. It grows cells to produce and test the candidates in the lab, then feeds the results back into its models to design better versions.
“它们结合得越紧密，你需要的量就越少，”首席执行官Nikolai Eroshenko告诉该报。“突然间，你就有了可以规模化的东西。”Eroshenko和联合创始人Hannu Rajaniemi于2025年从HelixNano分拆出这家公司。OpenAI领投了其种子轮融资，即去年11月宣布的1500万美元融资，参投方包括Cerberus Ventures、Fifty Years和Halcyon Futures。
“The tighter they bind, the less of them you need,” chief executive Nikolai Eroshenko told the Journal. “Suddenly, you have something that can scale.”Eroshenko and co-founder Hannu Rajaniemi spun the company out of HelixNano in 2025. OpenAI led its seed round, a $15 million raise announced last November, with Cerberus Ventures, Fifty Years and Halcyon Futures.
以AI速度防御“我们的使命是让生物防御的扩展速度快于前沿AI能力的增长，”该公司在其网站上表示。
Defence at AI speed“Our mission is to scale biological defenses faster than frontier AI capabilities grow,” the company says on its website.
Red Queen表示，它从不进行危险的功能获得性研究，也从不制造或分离危险病原体。
Red Queen says it never conducts dangerous gain-of-function research and never makes or isolates dangerous pathogens.
“攻击者想花多少时间开发生物武器都可以。我们没有数年时间来设计对策，”进步研究所生物技术研究员Olivia Scharfman告诉该报。
“The attackers have as much time as they want to develop a bioweapon. We don’t have years to design a countermeasure,” Olivia Scharfman, a biotechnology fellow at the Institute for Progress, told the Journal.
这家初创公司加入了AI和生物安全领域的其他努力。谷歌DeepMind于7月启动了一项AI生物安全计划。思科的一项研究发现，没有一种AI模型能完全抵御生物武器查询。上周，Anthropic的Dario Amodei请求联合国安理会支持禁止AI生物武器。
The startup joins other efforts on AI and biosecurity. Google DeepMind launched an AI biosecurity programme in July. A Cisco study found that no AI model was fully resistant to bioweapon queries. Last week, Anthropic’s Dario Amodei asked the UN Security Council to back a ban on AI bioweapons.